Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type 1 selected

Type

Guidance programme

Guidance programme

HealthTech approach

HealthTech approach

Area of interest

Showing 441 to 450 of 2039

TitleReference numberPublishedLast updated
Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal)TA901
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancerTA898
Tixagevimab plus cilgavimab for preventing COVID-19TA900
FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist careHTG682
Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and overTA893
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphomaTA894
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapyTA895
Bulevirtide for treating chronic hepatitis DTA896
Intraoperative electron beam radiotherapy for locally advanced and locally recurrent colorectal cancerHTG681
Daratumumab with bortezomib and dexamethasone for previously treated multiple myelomaTA897

Results per page

  1. 10
  2. 25
  3. 50
  4. All